RYTM - Rhythm's obesity therapy granted EU backing for orphan designation
2023-09-19 08:52:36 ET
More on Rhythm Pharma
- Seeking Alpha’s Quant Rating on Rhythm Pharmaceuticals
- Rhythm Pharmaceuticals: A Virtual Monopoly In Orphan Obesity Disorders
- Rhythm Pharmaceuticals: Growth, Uncertainty, And A 'Sell' Recommendation
- Rhythm Pharmaceuticals, Inc. 2023 Q2 - Results - Earnings Call Presentation
- Rhythm Pharma surges on strong Q2 sales; BofA upgrades
For further details see:
Rhythm’s obesity therapy granted EU backing for orphan designation